ID: ALA4518281

Max Phase: Preclinical

Molecular Formula: C38H65N5O12

Molecular Weight: 783.96

Molecule Type: Unknown

Representations

Canonical SMILES:  CCCCCCCCCCCCCCCCC[C@H]1CN[C@@H]([C@H](O[C@@H]2O[C@H](CN)[C@@H](O)[C@H]2O)[C@H]2O[C@@H](n3ccc(=O)[nH]c3=O)[C@H](O)[C@@H]2O)C(=O)N(C)[C@@H]1C(=O)O

Standard InChI:  InChI=1S/C38H65N5O12/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-23-22-40-26(34(49)42(2)27(23)36(50)51)32(55-37-31(48)28(45)24(21-39)53-37)33-29(46)30(47)35(54-33)43-20-19-25(44)41-38(43)52/h19-20,23-24,26-33,35,37,40,45-48H,3-18,21-22,39H2,1-2H3,(H,50,51)(H,41,44,52)/t23-,24+,26-,27-,28+,29-,30+,31+,32-,33-,35+,37-/m0/s1

Standard InChI Key:  KIJIAZHWTIZXMV-PIBSJNNQSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 783.96

Molecular Weight (Monoisotopic): 783.4630

AlogP: 0.71

#Rotatable Bonds: 23

Polar Surface Area: 259.13

Molecular Species: ZWITTERION

HBA: 14

HBD: 8

#RO5 Violations: 3

HBA (Lipinski): 17

HBD (Lipinski): 9

#RO5 Violations (Lipinski): 3

CX Acidic pKa: 3.53

CX Basic pKa: 8.75

CX LogP: 0.12

CX LogD: -0.03

Aromatic Rings: 1

Heavy Atoms: 55

QED Weighted: 0.07

Np Likeness Score: 1.06

References

1. Patel B, Ryan P, Makwana V, Zunk M, Rudrawar S, Grant G..  (2019)  Caprazamycins: Promising lead structures acting on a novel antibacterial target MraY.,  171  [PMID:30933853] [10.1016/j.ejmech.2019.01.071]

2. Okamoto K, Ishikawa A, Okawa R, Yamamoto K, Sato T, Yokota SI, Chiba K, Ichikawa S..  (2021)  Design, synthesis and biological evaluation of simplified analogues of MraY inhibitory natural product with rigid scaffold.,  55  [PMID:35016115] [10.1016/j.bmc.2021.116556]

Source

Source(1):

• Scientific Literature